Biotech
$YMI CYT387 Is Key Value Driver with Multiple Catalysts Expected in 2012
Written by Mike Havrilla–YM BioSciences (NYSEAMEX:YMI) is a small-cap biopharmaceutical company with three products currently in clinical development, including CYT387 (a small molecule dual inhibitor of the JAK1/JAK2 kinases), nimotuzumab (an EGFR-targeting monoclonal antibody), and CYT997 (a vascular disrupting agent or VDA).
Continue reading...$ASTX Cancer Biotech Trading Near Cash with Pending FDA (sNDA) Decision
11 January 2012 – 12:16 am PST
Comments Off
Written by Mike Havrilla–Astex Pharma (NASDAQ:ASTX) is a cancer biotech w/ an approved drug that is marketed by Japan-based Eisai along with a summary of the Company’s pending FDA and clinical trial catalysts below.
Continue reading...Webinar Tuesday January 10th at 4:30pm EST
10 January 2012 – 12:16 am PST
Comments Off
1/9/12 Clinical and Regulatory Calendar Summary
10 January 2012 – 12:16 am PST
Comments Off
$BDSI Seeks to Rebound from Phase 3 Setback
5 January 2012 – 12:16 am PST
Comments Off
Written by Mike Havrilla–BioDelivery Sciences (NASDAQ:BDSI) is a specialty pharmaceutical company that is focused on the development of pain drugs utilized in supportive cancer care that represent novel formulations of marketed drugs utilizing BioErodible MucoAdhesive (BEMA) Film Technology, which is designed for the rapid absorption and delivery of drugs into the bloodstream from the inside [...]
Continue reading...Spec Trade for Mike Trading at Cash Value with Insider Buying
5 January 2012 – 12:16 am PST
Comments Off
$NGSX Pain Drug Developer Awaits 1Q12 FDA (sNDA) Decision
5 January 2012 – 12:16 am PST
Comments Off
Written by Mike Havrilla–NeurogesX (NASDAQ:NGSX) is focused on the development and marketing of treatments for pain. Below is a summary of the Company’s currently approved pain drug skin patch which the Company markets in the US and is marketed by Astellas in Europe.
Continue reading...$OMER Pair of Phase 3 Results Expected Through Mid-2012 for Omeros
4 January 2012 – 12:16 am PST
Comments Off
Written by Mike Havrilla — Omeros (NASDAQ:OMER) is a bio-pharmaceutical company with a late-stage clinical development pipeline based on its PharmacoSurgery platform that is designed to improve the outcomes for surgical procedures such as knee and eye surgery.
Continue reading...
12 January 2012 – 12:16 am PST
Comments Off